Time to ignore Martin Shkreli?

One of the things that has pretty much united the pharmaceutical world is the deep dislike of ex-fund manager, Martin Shkreli.  He shot to fame in mid-2015 by hiking the price of the 65-year old generic toxoplasmosis drug, Daraprim, by 5,000% and then insulting anyone who was stupid enough to criticise the move.


Well, 2016 is a new year, it’s time to put these things behind us and be thankful of the good things…


In some ways, Mr Shkreli did the industry a service by raising the profile of drug pricing in an extremely efficient way. Every time the subject seems to be losing momentum – bang, there he would be with a new thing to inflame interested parties.


Apparently Mr Shkeli was arrested yesterday. The charges seem to stem from his former biotech company, Retrophin. The firm had sacked him and then sued him for using company shares to settle debts he racked up in his former hedge fund, MSMB Capital Management.


I have avoided writing about Mr Shkreli in these posts until now – after all, he seems to thrive on attention and gets enough elsewhere.


Maybe it’s time for him to sit on the naughty step for a good long time, with everyone ignoring him until he has thought about what he’s done.



Share on LinkedIn


Share via Email


                                    +21,000 STUDENTS        +9,400 COMPANIES          +100 COUNTRIES


Novartis logo                        NHS logo                        Takeda logo                        Roche logo                        DHL logo                        Baxter logo                        King's College logo                        US AID logo                        Novo Nordisk logo                           Grunenthal logo                           Wellcome logo                           Ipsen logo                           BTG logo